Cargando…

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)

5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine, Dacogen®) and 5-azacytidine (5-AC, Vidaza®) are epigenetic agents that have been approved for the clinical treatment of the hematological malignancy myelodysplastic syndrome (MDS) and are currently under clinical evaluation for the treatment of acute my...

Descripción completa

Detalles Bibliográficos
Autor principal:	Momparler, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763670/ https://www.ncbi.nlm.nih.gov/pubmed/24280679 http://dx.doi.org/10.3390/ph5080875

Ejemplares similares

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
por: Momparler, Richard L.
Publicado: (2013)

Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C
por: Momparler, Richard L., et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
por: Karahoca, Metin, et al.
Publicado: (2013)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
por: Momparler, Richard L, et al.
Publicado: (2014)

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells
por: Momparler, Richard L., et al.
Publicado: (2017)

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
por: Lemaire, Maryse, et al.
Publicado: (2008)

5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma.
por: Cortvrindt, R., et al.
Publicado: (1987)

Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the Transcriptome
por: Qiu, Xiangning, et al.
Publicado: (2010)

Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
por: Hurtubise, Annie, et al.
Publicado: (2008)

The Effect of 5-aza,2’-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK/STAT Pathways in Neuroblastoma and Glioblastoma Cells Lines
por: Sanaei, Masumeh, et al.
Publicado: (2023)

5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
por: Stübig, Thomas, et al.
Publicado: (2014)

5-Aza-2′-Deoxycytidine (5-Aza-dC, Decitabine) Inhibits Collagen Type I and III Expression in TGF-β1-Treated Equine Endometrial Fibroblasts
por: Alpoim-Moreira, Joana, et al.
Publicado: (2023)

Comment on “5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity”
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
por: Jansen, Yanina J L, et al.
Publicado: (2019)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
por: Richel, D. J., et al.
Publicado: (1991)

5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer
por: Patra, Aditi, et al.
Publicado: (2011)

Epigenetic regulation of the circadian clock: role of 5-aza-2′-deoxycytidine
por: Tomita, Tatsunosuke, et al.
Publicado: (2017)

Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth
por: Chiang, Tung-chin, et al.
Publicado: (2019)

5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1
por: Maslov, Alexander Y., et al.
Publicado: (2012)

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
por: Gu, Xiaorong, et al.
Publicado: (2020)

Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
por: Richel, D. J., et al.
Publicado: (1988)

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1
por: Bouchat, Sophie, et al.
Publicado: (2015)

DNA demethylation caused by 5-Aza-2′-deoxycytidine induces mitotic alterations and aneuploidy
por: Costa, Giuseppe, et al.
Publicado: (2016)

Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5‐Aza‐2′‐deoxycytidine
por: Shichijo, Shigeki, et al.
Publicado: (1996)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

Effects of 5-aza-2´-deoxycytidine on primary human chondrocytes from osteoarthritic patients
por: Kadler, Shirin, et al.
Publicado: (2020)

The Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Genome-Wide Hypomethylation in Rice
por: Liu, Shuo, et al.
Publicado: (2022)

Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells
por: Kim, Dae-Yeon, et al.
Publicado: (2021)

AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine
por: Tsai, Chiou-Tsun, et al.
Publicado: (2013)

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma
por: Hassler, Melanie R., et al.
Publicado: (2012)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine
por: Ding, Xiao-Lei, et al.
Publicado: (2016)

FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma
por: Geiger, Kathrin, et al.
Publicado: (2012)

Gene expression profiling of the synergy of 5-aza-2(′)-deoxycytidine and paclitaxel against renal cell carcinoma
por: Han, Tiandong, et al.
Publicado: (2012)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

DNA demethylation by 5-aza-2′-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences
por: Ramos, María-Paz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_83nddkvhlo2qvd7sa83aikdkv8